Astemizole
Astemizole (marketed under the brand name Hismanal, developmental code R43512) was a second-generation antihistamine drug that has a long duration of action. Astemizole was discovered by Janssen Pharmaceutica in 1977. It has been withdrawn from the market in most countries because of rare but potentially fatal side effects (QTc interval prolongation and related arrhythmias due to hERG channel blockade).
Ergogenic use of anabolic steroids
Anabolic steroid users tend to be disillusioned by the portrayal of anabolic steroids as deadly in the media and in politics. According to one study, anabolic steroid users also distrust their physicians, and in the sample, 56% had not disclosed their anabolic steroid use to their physicians. Another 2007 study showed that while 66% of individuals using anabolic steroids for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical anabolic steroid use was lacking, and 99% felt that the public has an exaggerated view of the side effects of anabolic steroid use. A 2006 study has showed that long-term anabolic steroid users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more traditional male roles.